KRAS and pancreatic neoplasm: Clinical studies have also shown that KRAS mutations could be considered as a marker for the poor prognosis of pancreatic cancer.17 However, it has been reported that various KRAS mutations affect diverse signaling pathways, leading to distinct functional consequences.